Paraoxonase 2 (PON2) Deficiency Reproduces Lipid Alterations of Diabetic and Inflammatory Glomerular Disease and Affects TRPC6 Signaling.
calcium signaling
lipid peroxidation
oxidative stress
podocyte
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
16 11 2022
16 11 2022
Historique:
received:
08
10
2022
revised:
31
10
2022
accepted:
11
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
Diabetes and inflammatory diseases are associated with an altered cellular lipid composition due to lipid peroxidation. The pathogenic potential of these lipid alterations in glomerular kidney diseases remains largely obscure as suitable cell culture and animal models are lacking. In glomerular disease, a loss of terminally differentiated glomerular epithelial cells called podocytes refers to irreversible damage. Podocytes are characterized by a complex ramified cellular architecture and highly active transmembrane signaling. Alterations in lipid composition in states of disease have been described in podocytes but the pathophysiologic mechanisms mediating podocyte damage are unclear. In this study, we employ a genetic deletion of the anti-oxidative, lipid-modifying paraoxonase 2 enzyme (PON2) as a model to study altered cellular lipid composition and its effects on cellular signaling in glomerular disease. PON2 deficiency reproduces features of an altered lipid composition of glomerular disease, characterized by an increase in ceramides and cholesterol. PON2 knockout mice are more susceptible to glomerular damage in models of aggravated oxidative stress such as adriamycin-induced nephropathy. Voltage clamp experiments in cultured podocytes reveal a largely increased TRPC6 conductance after a membrane stretch in PON2 deficiency. Correspondingly, a concomitant knockout of TRPC6 and PON2 partially rescues the aggravated glomerular phenotype of a PON2 knockout in the adriamycin model. This study establishes PON2 deficiency as a model to investigate the pathophysiologic mechanisms of podocyte dysfunction related to alterations in the lipid composition, as seen in diabetic and inflammatory glomerular disease. Expanding the knowledge on these routes and options of intervention could lead to novel treatment strategies for glomerular disease.
Identifiants
pubmed: 36429053
pii: cells11223625
doi: 10.3390/cells11223625
pmc: PMC9688324
pii:
doi:
Substances chimiques
TRPC6 Cation Channel
0
Aryldialkylphosphatase
EC 3.1.8.1
Doxorubicin
80168379AG
Lipids
0
Trpc6 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Lipid Res. 2009 May;50(5):870-9
pubmed: 19091699
Biochim Biophys Acta Mol Basis Dis. 2017 Sep;1863(9):2342-2354
pubmed: 28629718
Front Endocrinol (Lausanne). 2014 Jul 30;5:127
pubmed: 25126087
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
J Biol Chem. 2013 Aug 16;288(33):23914-27
pubmed: 23788644
J Clin Invest. 2006 May;116(5):1346-59
pubmed: 16543952
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
Am J Pathol. 2020 Jun;190(6):1211-1223
pubmed: 32194052
Cells. 2021 Mar 20;10(3):
pubmed: 33804736
Am J Pathol. 2004 Oct;165(4):1175-85
pubmed: 15466384
Nature. 1999 Jan 21;397(6716):259-63
pubmed: 9930701
Biochem Biophys Res Commun. 2018 Feb 5;496(2):394-400
pubmed: 29317203
Am J Physiol Renal Physiol. 2012 Nov 15;303(10):F1473-85
pubmed: 22975019
J Biol Chem. 2001 Nov 30;276(48):44444-9
pubmed: 11579088
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4979-84
pubmed: 23886683
Nephrology (Carlton). 2011 Jan;16(1):30-8
pubmed: 21175974
J Am Soc Nephrol. 2015 Sep;26(9):2097-104
pubmed: 25636411
Cell Death Dis. 2020 May 7;11(5):324
pubmed: 32382056
J Cell Biol. 2006 Nov 20;175(4):547-54
pubmed: 17101696
J Clin Invest. 2015 Nov 2;125(11):4091-106
pubmed: 26436650
J Am Soc Nephrol. 2002 Mar;13(3):630-638
pubmed: 11856766
Science. 2005 Jun 17;308(5729):1801-4
pubmed: 15879175
Nephron Exp Nephrol. 2007;106(2):e27-31
pubmed: 17570936
Acta Neurol Scand. 2008 Apr;117(4):237-43
pubmed: 17854416
Am J Physiol Cell Physiol. 2013 Nov 1;305(9):C960-71
pubmed: 23948707
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17079-86
pubmed: 17079490
FASEB J. 2014 Apr;28(4):1769-79
pubmed: 24421402
J Neurochem. 2009 Sep;110(5):1388-99
pubmed: 19545281
J Cell Physiol. 2012 Feb;227(2):550-7
pubmed: 21437908
Diabetologia. 2001 Jan;44(1):104-7
pubmed: 11206400
Am J Physiol Renal Physiol. 2015 Sep 1;309(5):F393-7
pubmed: 26084930
Am J Physiol Renal Physiol. 2014 May 1;306(9):F1088-97
pubmed: 24553432
J Am Soc Nephrol. 2018 Jul;29(7):1917-1927
pubmed: 29793963
J Am Soc Nephrol. 2018 Aug;29(8):2060-2068
pubmed: 29794128
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1551-6
pubmed: 24453217
J Lipid Res. 2005 Jun;46(6):1239-47
pubmed: 15772423
Physiol Int. 2021 Dec 16;:
pubmed: 34978536
Diabetes. 2009 Feb;58(2):337-43
pubmed: 19008343
PLoS One. 2013 Jul 31;8(7):e70002
pubmed: 23936132
Am J Physiol Renal Physiol. 2010 Oct;299(4):F689-701
pubmed: 20685822
Int J Endocrinol. 2013;2013:592576
pubmed: 24369464
Nature. 2002 Dec 12;420(6916):669-73
pubmed: 12478294
J Lipid Res. 2010 Jul;51(7):1719-28
pubmed: 19965614
Nat Rev Nephrol. 2020 May;16(5):251
pubmed: 32144399
Diabetes. 2013 Nov;62(11):3817-27
pubmed: 23835338
Sci Signal. 2010 Oct 26;3(145):ra77
pubmed: 20978238
Am J Physiol Renal Physiol. 2012 Feb 1;302(3):F298-307
pubmed: 22031853
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1041-1066
pubmed: 30953689
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16586-91
pubmed: 17056714
Nat Genet. 2005 Jul;37(7):739-44
pubmed: 15924139
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2070-5
pubmed: 14970312
J Am Soc Nephrol. 2019 Jan;30(1):96-108
pubmed: 30514724
J Biol Chem. 2001 Nov 9;276(45):41543-6
pubmed: 11562357
J Clin Invest. 2019 Jul 22;129(8):3387-3400
pubmed: 31329164
PLoS One. 2015 Dec 10;10(12):e0144579
pubmed: 26656916
Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1252-61
pubmed: 17916643
Oncotarget. 2016 Apr 5;7(14):19031-44
pubmed: 26980705
Nature. 2006 Apr 6;440(7085):818-23
pubmed: 16525419
J Am Soc Nephrol. 2009 Mar;20(3):473-8
pubmed: 19244577
Kidney Int. 2017 Apr;91(4):830-841
pubmed: 27979597
Am J Pathol. 2011 Nov;179(5):2210-9
pubmed: 21893018
Front Pharmacol. 2019 Dec 13;10:1487
pubmed: 31920669
Kidney Int. 2006 Dec;70(11):1962-73
pubmed: 17035936
J Mol Med (Berl). 2018 Jul;96(7):631-644
pubmed: 29785489
J Am Soc Nephrol. 2007 Jan;18(1):29-36
pubmed: 17167110
Mol Cell Biol. 2005 Aug;25(16):6980-9
pubmed: 16055711
Physiol Rev. 2003 Jan;83(1):253-307
pubmed: 12506131
JCI Insight. 2017 Aug 17;2(16):
pubmed: 28814668
Mol Genet Metab. 2009 Nov;98(3):314-8
pubmed: 19540141
J Biol Chem. 2006 Oct 6;281(40):29491-500
pubmed: 16891303
Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):468-74
pubmed: 12615656
Int J Exp Pathol. 2004 Feb;85(1):25-33
pubmed: 15113391
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10156-10161
pubmed: 31028142
Am J Hum Genet. 2003 Jan;72(1):13-22
pubmed: 12454802
J Hum Genet. 2013 May;58(5):254-8
pubmed: 23407349
Cell Death Dis. 2018 Mar 12;9(3):392
pubmed: 29531225
Am J Physiol Cell Physiol. 2013 Aug 1;305(3):C276-89
pubmed: 23657570
Klin Wochenschr. 1975 Jul 1;53(13):637-8
pubmed: 170451
J Cell Physiol. 2014 Apr;229(4):434-42
pubmed: 24037962
Front Endocrinol (Lausanne). 2021 Jan 28;11:622692
pubmed: 33584550
Br J Pharmacol. 2017 Nov;174(22):4099-4122
pubmed: 28800680
J Lipid Res. 2014 Mar;55(3):561-72
pubmed: 24371263